Drugs & Targets FDA grants Fast Track designation to IO-202, anti-LILRB4 myeloid checkpoint inhibitor for AML February 18, 2022Vol.48 No.07
In Brief Bill Cance to step down as ACS chief medical and scientific officer February 11, 2022Vol.48 No.06
In Brief AACI: Understanding catchment area coverage is key to mitigating cancer health disparities February 11, 2022Vol.48 No.06
In Brief Vince Jensen named City of Hope chief clinical operating officer February 11, 2022Vol.48 No.06
In Brief Kristin Ludwig named vice president of global corporate communications at EQRx February 11, 2022Vol.48 No.06
In Brief UChicago begins community engagement process for South Side cancer center February 11, 2022Vol.48 No.06
In Brief Brown University Legorreta Cancer Center announces 2022 Pilot Fund Awards February 11, 2022Vol.48 No.06
Trials & Tribulations Here’s how we can make clinical trials more inclusive February 11, 2022Vol.48 No.06By Jenny Sherak
Clinical Roundup ACS report: Breast cancer now leading cause of cancer death in African American/Black women February 11, 2022Vol.48 No.06
